Artiva Biotherapeutics (ARTV) Change in Accured Expenses (2023 - 2026)

Artiva Biotherapeutics (ARTV) has 4 years of Change in Accured Expenses data on file, last reported at -$4.0 million in Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 329.97% year-over-year to -$4.0 million in Q1 2026; TTM through Mar 2026 was -$1.1 million, a 173.62% decrease from a year earlier, with the FY2025 full-year figure at $2.0 million, up 403.95% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$4.0 million, down from $2.4 million in the prior quarter.
• Over the last five years, Change in Accured Expenses for ARTV reached as high as $3.1 million in Q3 2024 and fell as low as -$4.0 million in Q1 2026.
• Historically, Change in Accured Expenses has averaged -$261363.6 across 4 years, with a median of -$359000.0 in 2023.
• On a YoY basis, Change in Accured Expenses climbed as much as 964.07% in 2024 and fell as far as 793.71% in 2024.
• Year by year, Change in Accured Expenses stood at $143000.0 in 2023, then sank by 793.71% to -$992000.0 in 2024, then soared by 338.41% to $2.4 million in 2025, then plunged by 269.26% to -$4.0 million in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were -$4.0 million in Q1 2026, $2.4 million in Q4 2025, and $1.1 million in Q3 2025.